267 related articles for article (PubMed ID: 11240212)
1. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.
Stone TW
Prog Neurobiol; 2001 Jun; 64(2):185-218. PubMed ID: 11240212
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan metabolites and brain disorders.
Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
[TBL] [Abstract][Full Text] [Related]
3. Endogenous neurotoxins from tryptophan.
Stone TW
Toxicon; 2001 Jan; 39(1):61-73. PubMed ID: 10936623
[TBL] [Abstract][Full Text] [Related]
4. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
5. Basic mechanisms of kynurenine actions in the central nervous system.
Stone TW; MacGregor DG; Smith RA; Jones P; Behan WM; Graham DI
Adv Exp Med Biol; 1996; 398():195-201. PubMed ID: 8906266
[No Abstract] [Full Text] [Related]
6. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites.
Moroni F
Eur J Pharmacol; 1999 Jun; 375(1-3):87-100. PubMed ID: 10443567
[TBL] [Abstract][Full Text] [Related]
8. Central kynurenine pathway shift with age in women.
de Bie J; Guest J; Guillemin GJ; Grant R
J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
10. Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects.
Hertelendy P; Toldi J; Fülöp F; Vécsei L
Curr Med Chem; 2018; 25(42):5945-5957. PubMed ID: 29532751
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
12. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Németh H; Toldi J; Vécsei L
J Neural Transm Suppl; 2006; (70):285-304. PubMed ID: 17017544
[TBL] [Abstract][Full Text] [Related]
13. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
[TBL] [Abstract][Full Text] [Related]
14. Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Vecsei L; Plangar I; Szalardy L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):351-3. PubMed ID: 22943114
[No Abstract] [Full Text] [Related]
15. Metabolism and function of brain kynurenines.
Schwarcz R
Biochem Soc Trans; 1993 Feb; 21(1):77-82. PubMed ID: 8449358
[No Abstract] [Full Text] [Related]
16. Kynurenines in the CNS: recent advances and new questions.
Vécsei L; Szalárdy L; Fülöp F; Toldi J
Nat Rev Drug Discov; 2013 Jan; 12(1):64-82. PubMed ID: 23237916
[TBL] [Abstract][Full Text] [Related]
17. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.
Zádori D; Veres G; Szalárdy L; Klivényi P; Vécsei L
J Alzheimers Dis; 2018; 62(2):523-547. PubMed ID: 29480191
[TBL] [Abstract][Full Text] [Related]
19. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
Heyes MP; Brew BJ; Saito K; Quearry BJ; Price RW; Lee K; Bhalla RB; Der M; Markey SP
J Neuroimmunol; 1992 Sep; 40(1):71-80. PubMed ID: 1387655
[TBL] [Abstract][Full Text] [Related]
20. Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
Török N; Majláth Z; Fülöp F; Toldi J; Vécsei L
Curr Drug Metab; 2016; 17(5):412-29. PubMed ID: 26694727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
